Stocktoria
ELI LILLY & Co LLY
NYSE · stock · Pharmaceutical Preparations · website · IPO 1970-07-09
ELI LILLY & Co financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.2B | $45.0B | $34.1B | $28.5B | $28.3B | $24.5B | $22.3B | $21.5B | $20.0B | $21.2B |
| R&D expense | — | — | — | $7.2B | $6.9B | $6.0B | $5.6B | $5.1B | $5.1B | $5.3B |
| SG&A expense | $11.1B | $8.6B | $7.4B | $6.4B | $6.4B | $6.1B | $6.2B | $6.0B | $6.0B | $6.5B |
| Interest expense | — | — | $485.9M | $331.6M | $339.8M | $359.6M | $400.6M | $242.5M | $225.0M | $185.2M |
| Income tax | $5.1B | $2.1B | $1.3B | $561.6M | $573.8M | $1.0B | $628.0M | $529.5M | $2.4B | $636.4M |
| Net income | $20.6B | $10.6B | $5.2B | $6.2B | $5.6B | $6.2B | $8.3B | $3.2B | -$204.1M | $2.7B |
| EPS (diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 | $3.13 | $-0.19 | $2.58 |
| Operating cash flow | $16.8B | $8.8B | $4.2B | $7.6B | $7.4B | $6.5B | $4.8B | $5.5B | $5.6B | $4.9B |
| Cash & equivalents | $7.3B | $3.3B | $2.8B | $2.1B | $3.8B | $3.7B | $2.3B | $7.3B | $6.5B | $4.6B |
| Inventory | $13.7B | $7.6B | $5.8B | $4.3B | $3.9B | $4.0B | $3.2B | $3.1B | $4.5B | $3.6B |
| Total assets | $112.5B | $78.7B | $64.0B | $49.5B | $48.8B | $46.6B | $39.3B | $43.9B | $45.0B | $38.8B |
| Shareholders' equity | $26.5B | $14.3B | $10.9B | $10.8B | $9.2B | $5.8B | $2.7B | $10.9B | $11.7B | $14.1B |
Growth · year-over-year · Revenue CAGR 13.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +44.7% | +32.0% | +19.6% | +0.8% | +15.4% | +9.9% | +3.8% | +7.6% | -5.9% | +6.3% |
| Net income growth | +94.9% | +102.1% | -16.1% | +11.9% | -9.9% | -25.5% | +157.4% | — | -107.5% | +13.7% |
| EPS growth | +96.0% | +101.9% | -15.9% | +12.7% | -9.9% | -23.6% | +184.0% | — | -107.4% | +14.2% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.